An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

Exclusion Criteria

• •Finerenone users who are hospitalized or admitted for an emergency department visit on Time 0
• •Type 1 diabetes (T1D) at any time on or before Time
• •Evidence of end-stage kidney disease (ESKD) at any time on or before Time 0
• •A diagnosis of kidney cancer at any time on or before Time 0
• •A diagnosis of adrenal insufficiency at any time on or before Time 0
• •Evidence of hepatic impairment at any time on or before Time 0
• •An eGFR measurement \< 25 mL/min/1.73 m2 on or in the 90 days before Time 0
• •Evidence of recent increased serum potassium or hyperkalaemia
• •Use of a strong CYP3A4 inhibitor on or in the 183 days before Time 0
• •Evidence of pregnancy measured on or in the 40 weeks before Time 0